Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADH1B | P00325 | 3/20 | 0.38 |
| ▸ | ADH1A | P07327 | 3/20 | 0.38 |
| ▸ | ADH7 | P40394 | 3/20 | 0.38 |
| ▸ | ADH1C | P00326 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8129476 | 0.88 | SIGMAR1 (0.41) | ADH1BADH1AADH7ADH1CSIGMAR1 | |
| SCHEMBL8763412 | 0.84 | LMNA (0.50) | LMNAADH1BADH1AADH7ADH1C | |
| SCHEMBL8763272 | 0.78 | LMNA (0.46) | LMNAADH1BADH1AADH7ADH1C | |
| SCHEMBL6566420 | 0.78 | ADH1B (0.61) | ADH1BADH1AADH7ADH1CMEN1 | |
| SCHEMBL56059 | 0.78 | ADH1B (0.61) | LMNAADH1BADH1AADH7ADH1C | |
| SCHEMBL27281796 | 0.76 | — | — | |
| SCHEMBL23266841 | 0.75 | GFER (0.52) | LMNAADH1BADH1AADH7ADH1C | |
| SCHEMBL2807183 | 0.75 | ALDH1A1 (0.50) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10433880 | 0.75 | ADH1B (0.50) | LMNAADH1BADH1AADH7ADH1C | |
| SCHEMBL16404456 | 0.75 | L3MBTL1 (0.50) | LMNAADH1BADH1AADH7ADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | LMNA 1736/4885ADH1B 3869/4885ADH1A 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.